Nortal Investments Acquires Additional Shares in PledPharma

        Print
| Source: PledPharma AB
multilang-release

Stockholm, 2013-01-09 15:37 CET (GLOBE NEWSWIRE) -- Staffan Persson, Nortal Investments AB, PledPharma’s largest shareholder, has acquired an additional 100 000 shares in PledPharma. This means that Staffan Persson’s family and company owns a total of 5, 068,052 shares. After the acquisition, Nortal Investments’ stake in PledPharma is estimated to 25% of the votes and capital.

“PledPharma has just begun a key phase llb study where the company carries out a clinical trial in humans on its patented substance PledOx. If PledPharma succeeds with this study it can lead to significant opportunities for the company, as PledOx can reduce serious side effects of chemotherapy when treating cancer. Obviously one should be humble, given the development phase the company is in. But if PledPharma succeeds then shareholders will be highly rewarded”, says Staffan Persson, Nortal Investment.

“We are glad that Nortal Investment proceeds to invest in PledPharma. It is reassuring that the largest shareholder have a continued confidence in our business”, says PledPharma’s CEO Jacques Näsström.

For further information please contact

Staffan Persson, Nortal Investments, sp@swediacapital.se

Jacques Näsström, CEO PledPharma, +46 737 13 09 79, jacques.nasstrom@pledpharma.se

 

About PledPharma

PledPharma is a Swedish specialty pharma company that develops a new medicine, PledOx™, for prevention of the severe side effects that patients develop as a consequence of chemotherapy treatment of cancer. Many times the treatment cannot be carried out as planned due to very difficult side effects. The current market for supportive cancer care is some SEK 72 billion. PledOx is a medicine within the patent protected substance class PLED, which protects the body’s normal cells against oxidative stress. Oxidative stress is a condition where an overabundance of harmful oxygen molecules (free oxygen radicals) has been formed. We are also evaluating opportunities with PLED substances for other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For further information, please visit www.pledpharma.se